Nevertheless, cancer cells can always find ways to bypass TGF-β-mediated inhibition, in turn taking advantage of TGF-β signaling or directly producing TGF-β to benefit themselves (Biswas et al., 2014; Yang et al., 2016a; Tang et al., 2017; Rasti et al., 2021). This evidence concerns the gene TGFB1 and cancer.